Good News | "Breast Tissue Marker Localization Needle" Approved for Market Launch!

Recently, the Breast Tissue Marker Localization Needle, independently developed by a subsidiary of Mednovo Group, has successfully obtained approval from the National Medical Products Administration (NMPA) for market release (Registration No.: 国械注准20253021366). This marks the 39th medical device registration certificate achieved by Mednovo Group and represents another milestone product in the field of women's health. The device is designed to advance early detection, precise diagnosis, and targeted treatment of breast cancer, ultimately improving patients' quality of life.

Breast Tissue Marker Localization Needle

This product is used for intraoperative localization and marking of breast tissue during biopsy procedures. Indications：

non-palpable suspicious breast lesions for open surgical biopsy； non-palpable breast cancer lesions for breast-conserving surgery.；

Marking of breast cancer lesions prior to neoadjuvant therapy in patients planned for breast-conserving surgery；

Patients with cT1–3N1M0 breast cancer and confirmed axillary lymph node metastasis by needle biopsy, planned for axillary preservation after neoadjuvant therapy.

Features:

1. Precise Localization & Permanent Visibility:

Enhanced ultrasound visibility of the needle tip.

Marker size: ~3 mm.

PVA material ensures permanent visibility for accurate positioning.

2. Accurate Marker Placement:

17G puncture needle with 1 cm interval markings for precise marker deployment.

3. User-Friendly Operation:

Color-coded release buttons differentiate marker shapes.

Dual release buttons for flexible and intuitive operation.